Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthias Kretzler

Nephrology Ann Arbor, MI Medical Doctor

NPI 1710990916 CMS profile 981899

1500 E Medical Center Dr, Ann Arbor, MI 48109

Open in the dashboard

General payments

$70,309

89 records reported · program years 2019–2025

Research payments

$2,250

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,685,311 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Matthias Kretzler of Ann Arbor, MI is reported in the CMS Open Payments database as having received $70,309 across 89 general payments and $2,250 in research payments paid to them. Separately, studies naming them as principal investigator received $7,685,311 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Nephrology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,106 21
2024 General $17,423 20
2023 General $1,835 8
2023 Research $2,250 1
2022 General $8,904 8
2021 General $11,550 6
2020 General $13,755 10
2019 General $8,737 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthias Kretzler
  • Nephrology median
  • Middle half of Nephrology
  • National median

In program year 2025, general payments to Matthias Kretzler were reported at $8,106. Among 8,186 Nephrology profiles paid that year, the median was $310 and the middle half received between $104 and $880.

Show as a table
Year Matthias Kretzler Nephrology median Middle half National median
2019 $8,737 $236 $90–$588 $163
2020 $13,755 $135 $46–$364 $114
2021 $11,550 $202 $67–$551 $132
2022 $8,904 $242 $77–$695 $149
2023 $1,835 $254 $84–$766 $160
2024 $17,423 $300 $99–$852 $164
2025 $8,106 $310 $104–$880 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim International GmbH $20,398 16 payments
  2. Novo Nordisk AS $10,795 7 payments
  3. Otsuka Pharmaceutical Development & Commercialization, Inc. $10,361 10 payments
  4. Regeneron Pharmaceuticals, Inc. $6,268 11 payments
  5. Gilead Sciences, Inc. $6,088 6 payments
  6. Janssen Research & Development, LLC $6,000 1 payment
  7. Novartis Pharmaceuticals Corporation $5,997 6 payments
  8. Retrophin, Inc. $3,923 20 payments
  9. AstraZeneca UK Limited $143 4 payments
  10. Apellis Pharmaceuticals, Inc. $139 1 payment
  11. Other $198 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $57,046 21 payments
  2. Travel and Lodging $9,155 31 payments
  3. Food and Beverage $2,783 35 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,325 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $3,520 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Novo Nordisk Inc $2,250 1 payment

Records

90 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nephrology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record